Symbol="IMAB"
AssetType="Common Stock"
Name="I-Mab"
Description="I-Mab, a clinical-stage biopharmaceutical company, discovers, develops and markets biologics to treat cancer and autoimmune disorders. The company is headquartered in Shanghai, the People's Republic of China."
CIK="1778016"
Exchange="NASDAQ"
Currency="USD"
Country="China"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="SUITE 802, WEST TOWER, OMNLVISION, 88 SHANGKE ROAD, PUDONG DISTRICT, SHANGHAI, CHINA"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="157397000"
EBITDA="-1859417984"
PERatio="None"
PEGRatio="None"
BookValue="29.48"
DividendPerShare="0"
DividendYield="0"
EPS="-3.71"
RevenuePerShareTTM="-3.057"
ProfitMargin="0"
OperatingMarginTTM="6.8"
ReturnOnAssetsTTM="-0.254"
ReturnOnEquityTTM="-0.662"
RevenueTTM="-253766000"
GrossProfitTTM="41594000"
DilutedEPSTTM="-3.71"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.621"
AnalystTargetPrice="29.08"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="2.545"
PriceToBookRatio="0.587"
EVToRevenue="0.439"
EVToEBITDA="0.101"
Beta="0.931"
num_52WeekHigh="7.67"
num_52WeekLow="1.9"
num_50DayMovingAverage="2.842"
num_200DayMovingAverage="3.756"
SharesOutstanding="82623000"
DividendDate="None"
ExDividendDate="None"
symbol="IMAB"
open="2.06"
high="2.10"
low="1.90"
price="1.91"
volume="748927.00"
latest_trading_day="2023-08-21"
previous_close="2.10"
change="-0.20"
change_percent="-9.2857%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="92"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Trending High"
value_analysis="Bullish Trend"
Aroon_change="FALSE"
Aroon_momentum="8"
Volume_recent_avg="345626"
Change_recent_avg="-0.01"
Delta_recent_avg="0.2"
Variance_recent_avg="0.1"
Change_ratio_recent_avg="-0.41"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="8"
Aroon_momentum_negative="92"
image_negative_thumbnail_id_1="93"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0083.jpeg"
image_negative_thumbnail_id_2="118"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0058.jpeg"
image_neutral_thumbnail_id_1="578"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0021.jpeg"
image_neutral_thumbnail_id_2="547"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0052.jpeg"
image_positive_thumbnail_id_1="694"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0014.jpeg"
image_positive_thumbnail_id_2="650"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0058.jpeg"
image_professor_thumbnail_id_1="1198"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0032.jpeg"
image_professor_thumbnail_id_2="1194"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0028.jpeg"
